<DOC>
	<DOCNO>NCT01898520</DOCNO>
	<brief_summary>A study assess effect Sativex treatment spasticity population child adolescent age 8 18 year cerebral palsy traumatic central nervous system injury . Efficacy ( ability improve symptom ) , safety tolerability monitor .</brief_summary>
	<brief_title>A Safety , Efficacy Tolerability Study Sativex Treatment Spasticity Children Aged 8 18 Years</brief_title>
	<detailed_description>A 12 week randomise , double-blind , placebo-controlled , parallel group study follow 24-week open-label extension phase . The primary objective ass efficacy Sativex treatment use spasticity 0-10 numerical rating scale ( NRS ) . The endpoint analysis comparison Sativex placebo change baseline end acute phase mean spasticity 0-10 NRS score ( week 12 last seven day prior withdrawal ) . The secondary objective assess safety tolerability Sativex via volunteered adverse event , laboratory parameter vital sign . The efficacy Sativex compare placebo also investigate follow outcome : spasticity ( modify tardieu scale ( MTS ) score affect limb modify ashworth scale ( MAS ) score main muscle group upper low limb ) , sleep quality ( sleep 0-10 NRS ) , pain ( paediatric pain profile [ PPP ] ) , quality life ( participant caregiver ; cerebral palsy quality life ( QOL ) questionnaire caregiver QOL questionnaire ) , comfort ( comfort questionnaire ) , depression assessment ( childrens depression inventory ( CDI 2 ) ) caregiver 's global impression change ( CGIC ) .</detailed_description>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Peppermint oil</mesh_term>
	<criteria>Males female age 8 18 year suffer cerebral palsy traumatic central nervous system injury . Participant and/or authorise representative willing able give inform consent participation study . To treatment spasticity least one year reach stage nonprogressive spasticity . Participant able ( investigator opinion ) willing comply study requirement . Participant receive inadequate efficacy and/or experience unacceptable side effect previous current treatment least one follow medication spasticity : Baclofen , Diazepam ( another benzodiazepine ) , Dantrolene , Tizanidine , Gabapentin , Trihexyphenidyl . Gross Motor Function Classification Scale Level III V. MAS two high least one muscle group . Participant and/or authorise representative willing name notify responsible authority participation study , applicable individual country . Participant and/or authorise representative willing allow primary care practitioner consultant , appropriate , notified participation study . Any known suspected history : Schizophrenia psychotic illness , diagnosis schizophrenia firstdegree relative . Alcohol substance abuse . Any known suspected hypersensitivity cannabinoids excipients IMP ( ) Use cannabis cannabinoid base medication ( include within 30 day 60 day study entry respectively ) . Weight le 15 kg . Female participant child bear potential male participant whose partner child bear potential , unless willing ensure partner use effective contraception study three month thereafter . Female participant pregnant , lactate plan pregnancy course study three month thereafter . Participants receive Investigational Medicinal Product ( IMP ) within 12 week prior screen visit . Has treat botulinum toxin previous 12 week . Concomitant use botulinum toxin Any significant disease disorder , , opinion investigator , may either put participant risk participation study , may influence result study , participant 's ability participate study . Following physical examination , participant abnormality , opinion investigator would prevent participant safe participation study . Significant cardiac , renal hepatic disease . Planned surgical procedure randomise phase study . Travel outside country residence plan study . Participants previously randomise study . Unwilling abstain donation blood study</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Spasticity</keyword>
</DOC>